Dostarlimab: A breakthrough in the field of oncology.

导出 LinkOut

翻译打印收藏纠错

作者： Hassan Ul,Hussain ^[1] ; Muhammad Husban,Burney ^[2] ; Syeda Tayyaba,Rehan ^[1] ; Mohammad Mehedi,Hasan ^[3]

作者单位： Dow University of Health Sciences, Karachi, Pakistan. ^[1] Karachi Medical and Dental College, Karachi, Pakistan. ^[2] Department of Biochemistry and Molecular Biology, Faculty of Life Science, Mawlana Bhashani Science and Technology University, Tangail, Bangladesh. ^[3]

关键词 CCR therapy CRC, colorectal cancer Cancer Dostarlimab FDA, Food and Drug Administration GDP, gross domestic product LMIC, lower-middle-income country MMRd, mismatch repair-deficiency MRI, magnetic resonance imaging NSCLC, non-small cell lung cancer PD-1, programmed death 1 PD-L1, programmed death 1 ligand 1 PET, positron emission tomography Pakistan SCLC, small-cell lung cancer Treatment

DOI 10.1016/j.amsu.2022.104046

PMID 36045764

发布时间 2022-09-07

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Annals of medicine and surgery (2012)

2022年80卷

104046页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Dostarlimab: A breakthrough in the field of oncology.

Annals of medicine and surgery (2012)

相似文献

Annals of medicine and surgery (2012)

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Dostarlimab: A breakthrough in the field of oncology.

Annals of medicine and surgery (2012)

相似文献

Annals of medicine and surgery (2012)

相关期刊

检索历史清除